Custom Tailoring Therapy for Breast Cancer Using ERBB-2
Annual rept. 15 Dec 1992-31 Dec 1993
GEORGETOWN UNIV WASHINGTON DC
Pagination or Media Count:
In order to examine whether erbB-2 protein over-expression influence the survival and tamixifen response in ER positive node negative breast cancer, 937 patients were examined from NSABP trial B-14. No such effect was found. ERBB-2, Breast cancer, Tamoxifen, Estrogen receptor, Survival, Therapy.
- Medicine and Medical Research